Biosyent Inc.
Research Biosyent Inc. (RX) on Bullrun: market cap CAD 176.48M, P/E 18.4, dividend yield 1.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRX
- ExchangeV
- CountryCanada
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCAD
- Market capCAD 176.48M
- P/E18.4
- Dividend yield1.0%
- Financial periodQ1 2026
- RevenueCAD 13.91M
- Net incomeCAD 2.34M
- Free cash flowCAD 2.69M
- Gross margin73.1%
Valuation Snapshot
latest market cap is CAD 176.48M; P/E is 18.4; dividend yield is 1.0%.
Peer valuation comparison
Latest P/E is 18.35x versus a Healthcare sector median of 24.46x (25.0% below).
Latest dividend yield is 1.02% versus a Healthcare sector median of 2.11% (51.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 43.05M | CAD 9.01M | CAD 8.62M | 76.6% | 0.79 | CAD 21.79M | CAD 841.10K | CAD 41.47M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | CAD 176.48M | 18.4 | 1.4% | 0.22 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.22 CAD, yield 1.0%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.2 CAD |
About Biosyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Biosyent Inc.'s market cap?
Biosyent Inc.'s market capitalization is CAD 176.48M.
What is Biosyent Inc.'s P/E ratio?
Biosyent Inc.'s price-to-earnings (P/E) ratio is 18.4.
Does Biosyent Inc. pay a dividend?
Biosyent Inc. has a dividend yield of 1.0%.
What does Biosyent Inc. do?
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.